Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Bills Supporting Device Opioid Alternatives Advance In House

Executive Summary

The House Energy and Commerce Committee approved four opioid crisis-related bills that call for US FDA meetings and consideration of streamlined pathways for medtech alternatives to opioids, and for a report and action by the US Medicare agency on overcoming payment challenges to device pain control products.

You may also be interested in...



Payment 'Sunshine' Requirements Would Expand For Industry Under Senate-Passed Opioid Bill

A provision to expand Sunshine Act industry reporting requirements for companies in the Senate-passed “Opioid Crisis Response Act” has caught criticism from the device sector, despite overall industry support for the legislation.

Bills Calling For Non-Pharma Alternatives To Opioids Clear US House

Several bills that try to lift barriers to development and use of device alternatives for pain management in response to the opioid crisis were recently approved by the US House.

Senate Opioids Bill Would Add Sunshine Provisions, Expand Medicare Telehealth Services

Senators on June 12 advanced a bill addressing the opioid crisis from the Finance Committee, including sunshine provisions expanding the types of providers that must report payments of value by drug and device manufacturers, requiring an essential Medicare handbook to describe non-opioid alternatives for pain control, and expanding telehealth payments for providers treating beneficiaries with substance use disorders.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

MT122694

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel